Materias dentro de su búsqueda.
Mostrando 82,041 - 82,060 Resultados de 84,353 Para Buscar '"HR"', tiempo de consulta: 0.81s Limitar resultados
  1. 82041
    “…Adjusted hazard ratios (HRs) were derived from 1:1 matching adjusted across potential covariates. rVE was (1 – HR(adjusted)) × 100. Additional analysis was performed across regions and age groups. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Relative Effectiveness of BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines and Homologous Boosting in Preventing COVID-19 in Adults in the US
  2. 82042
    “…In pooled Cox regression analysis, T1D was not a determinant of mortality (HR 1.18 (95% CI 0.71 to 1.97), p=0.523). CONCLUSIONS: T1D substantially increases the risk of death, especially when diagnosed in late adolescence/young adulthood. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Comparative mortality and its determinants in community-based people with type 1 diabetes: the Fremantle Diabetes Study Phase I
  3. 82043
    “…P-NfL levels in the highest quartile were associated with incident CKD at follow-up (HR; 2.39 [1.21: 4.72]). DISCUSSION: In a community-based cohort of 70-year olds, P-NfL was associated with both prevalent and incident CKD, while CSF and/or imaging measures did not differ by CKD status. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Association of Chronic Kidney Disease With Plasma NfL and Other Biomarkers of Neurodegeneration: The H70 Birth Cohort Study in Gothenburg
  4. 82044
    “…Adjusted comparisons showed that patients treated with cilta-cel were 3.12-fold more likely to respond to treatment than those managed by RWCP (response rate, 3.12, 95% confidence interval [95% CI]: 2.24-4.00), had their risk of progression or death reduced to by 85% (progression-free survival hazard ratio=0.15, 95% CI: 0.08-0.29), and a risk of death lowered by 80% (overall survival hazard ratio HR=0.20, 95% CI: 0.09-0.41). The incremental improvement in health-related quality of life from baseline for cilta-cel versus RWCP at week 52, as measured by EORTC QLQ-C30 Global Health Status, was 13.4 (95% CI: 3.5-23.6) and increased to 30.8 (95% CI: 21.8-39.8) when including death as additional information regarding patients’ health status. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice
  5. 82045
    por Lluís, Núria, Serradilla-Martín, Mario, Achalandabaso, Mar, Jehaes, François, Dasari, Bobby V.M., Mambrilla-Herrero, Sara, Sparrelid, Ernesto, Balakrishnan, Anita, Hoogwater, Frederik J.H., Amaral, Maria J., Andersson, Bodil, Berrevoet, Frederik, Doussot, Alexandre, López-López, Víctor, Alsammani, Mohammedsuror, Detry, Olivier, Domingo-del Pozo, Carlos, Machairas, Nikolaos, Pekli, Damján, Alcázar-López, Cándido F., Asbun, Horacio, Björnsson, Bergthor, Christophides, Thalis, Díez-Caballero, Alberto, Francart, David, Noel, Colin B., Sousa-Silva, Donzília, Toledo-Martínez, Enrique, Tzimas, George N., Yaqub, Sheraz, Cauchy, François, Prieto-Calvo, Mikel, D’Souza, Melroy A., Spiers, Harry V.M., van den Heuvel, Marius C., Charco, Ramón, Lesurtel, Mickaël, Ramia, José M.
    Publicado 2023
    “…Multivariable Cox regression analysis showed that not achieving TO (HR: 4.20; 95% CI: 1.11–15.94; P=0.03) was an independent prognostic factor of poor overall survival. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Intraductal papillary neoplasms of the bile duct: a European retrospective multicenter observational study (EUR-IPNB study)
  6. 82046
    “…METHODS: Data were retrospectively collected for patients with HR-positive+/HER2−negative MBC who received ribociclib with an aromatase inhibitor (AI) or fulvestrant and were divided into two groups: HER2-zero and HER2-low. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Differences in Treatment Outcomes Between Patients with HER2-Low versus HER2-Zero, Hormone Receptor-Positive Advanced-Stage Breast Cancer Treated with Ribociclib
  7. 82047
    “…CCP patients also reached the A1c goal significantly faster: 3.4 months versus 4.6 months (P < 0.0001), even after controlling for covariates (HR = 1.24, 95% CI = 1.09-1.41, P = 0.001). Change in baseline A1c was -0.95% versus -0.54% (P < 0.0001) at 3 months and -1.19% versus -0.99% (P = 0.008) at 6 months for CCP versus UC patients, respectively. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Evaluation of a Pharmacist-Managed Diabetes Program in a Primary Care Setting Within an Integrated Health Care System
  8. 82048
    “…Median i-PFS was 16.0 months (range 7-80): low pSTAT3 BM (score 0-1) had a median i-PFS of 11 months versus 8 months for high pSTAT3 BM (score 2-3) (HR 0.4; p=0.0123). A shorter median i-PFS was observed in high pSTAT3 triple negative BM (4 months) as compared with low pSTAT3 BM (20 months). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    BSBM-12 STAT3 EXPRESSION IN BRAIN METASTASES FROM BREAST CANCER: CORRELATIONS WITH DIFFERENT MOLECULAR SUBTYPES AND CLINICAL OUTCOME
  9. 82049
    por Bernal, Teresa, Moreno, Ainhoa Fernández, de LaIglesia, Almudena, Benavente, Celina, García‐Noblejas, Ana, Belmonte, Daniel García, Riaza, Rosalía, Salamero, Olga, Foncillas, Maria Angeles, Roldán, Alicia, Concepción, Víctor Noriega, González, Laura Llorente, Bergua Burgués, Juan Miguel, Lorente de Uña, Soraya, Rodríguez‐Macías, Gabriela, de la Fuente Burguera, Adolfo, García Pérez, Maria José, López‐Lorenzo, Jose Luis, Martínez, Pilar, Aláez, Concepción, Callejas, Marta, Martínez‐Chamorro, Carmen, Roca, José Rifón, Barciela, Lourdes Amador, Mena Durán, Armando V., Gómez Correcha, Karoll, Lavilla Rubira, Esperanza, Amigo, María Luz, Vall‐llovera, Ferran, Garrido, Ana, García‐Fortes, María, de Miguel Llorente, Dunia, Leonardo, Anastasia Aules, Cervero, Carlos, Jordá, Rosa Coll, Pérez‐Encinas, Manuel M., Zarzuela, Marta Polo, Figuera, Angela, Rad, Guillermo, Martínez‐Cuadrón, David, Montesinos, Pau
    Publicado 2023
    “…In multivariable analyses, SCT was associated with better OS (HR 0.33 95% CI: 0.18–0.59), p < 0.001. CONCLUSION: Larger post‐authorization studies may provide evidence of the clinical benefits of CPX‐351 for AML in the real‐life setting.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Clinical outcomes after CPX‐351 in patients with high‐risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry
  10. 82050
    “…A strong to very strong correlation between s-RPE and HR was observed (overall: r = 0.74; CR-10: r = 0.69; CR-100: r = 0.80). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A meta-analysis of the criterion-related validity of Session-RPE scales in adolescent athletes
  11. 82051
    “…Multivariate analysis revealed association of Eastern Cooperative Oncology Group (ECOG) performance status score with PFS and superior benefits for non-gastric was observed as compared to gastric GISTs [hazard ratio (HR) 0.58, 95% CI (0.39–0.86)]. Disease control rate and tumor shrinkage (any magnitude) was 73% and 43%, respectively. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Large-Scale, Multicenter, Prospective Registry Study of Ripretinib in Advanced GIST: A Real-World Study from China
  12. 82052
    “…SGLT2i use was associated with a nonsignificantly lower risk of ACS (adjusted HR 0.95, 95%confidence intervals (CI 0.87–1.04, P = 0.3218). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The association between SGLT2 inhibitors and new-onset acute coronary syndrome in the elderly: a population-based longitudinal cohort study
  13. 82053
    “…Survival analysis indicated that the higher Mor-index correlated with better OS in the discovery cohorts (HR for high vs. low 0.49, 95% CI 0.27–0.77, P = 0.0014) and validation cohort (0.21, 0.10–0.46, < 0.0001). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    An artificial intelligence-based ecological index for prognostic evaluation of colorectal cancer
  14. 82054
    “…Receipt of adjuvant chemotherapy was independently associated with a decreased hazard of death (hazard ratio (HR), 0.37; 95% confidence intervals (CI), 0.20–0.68; P = 0.002). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The efficacy of adjuvant chemotherapy for older adults with stage II/III gastric cancer: a retrospective cohort study
  15. 82055
    “…ABCD-GENE score ≥10 was associated with an increased risk of vascular events (HR 1.13, 95% CI 1.03–1.23). In aspirin users, and in non-users of either aspirin or clopidogrel, the ABCD-GENE score was also associated with increased risk of vascular events. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The ABCD-GENE score influences vascular event rates in both users of clopidogrel and aspirin, as well as non-users of either drug in a population-based cohort study
  16. 82056
    “…In addition, Cox analysis showed that LV entropy provided significant prognostic value for predicting both primary and secondary endpoints (HR: 1.291 and 1.273, all p < 0.001). Addition of LV entropy to the multivariable model improved model performance and risk reclassification (p < 0.05). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Late gadolinium enhancement entropy as a new measure of myocardial tissue heterogeneity for prediction of adverse cardiac events in patients with hypertrophic cardiomyopathy
  17. 82057
    “…Observational analyses suggested no significant association of migraine with the risk of CKD (HR = 1.13, 95% CI = 0.85–1.50). While we did not find any global genetic correlation in general, we identified four specific genomic regions showing significant for migraine with eGFR. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Migraine, chronic kidney disease and kidney function: observational and genetic analyses
  18. 82058
    “…Results: The adjusted hazard ratio (aHR) comparing vitamin D supplementation to no supplementation was 0.44 (95% CI 0.29–0.69; p < 0.0001), demonstrating a significant decrease in the risk of dementia associated with vitamin D supplementation. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The Protective Effect of Vitamin D on Dementia Risk in Hemodialysis Patients
  19. 82059
    “…Meta-analysis showed that detrimental SASP group had significantly higher risk of biochemical recurrence (BCR) than beneficial SASP group (HR: 2.48). Moreover, we also constructed and validated risk score based on these genes to better guide clinical practice. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Senescence-associated secretory phenotype constructed detrimental and beneficial subtypes and prognostic index for prostate cancer patients undergoing radical prostatectomy
  20. 82060
    “…The adjusted hazard ratio (aHR) of care needs level deterioration was 0.69 (95% confidence interval (CI): 0.51–0.93). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Association of housing adaptation services with the prevention of care needs level deterioration for older adults with frailty in Japan: a retrospective cohort study
Herramientas de búsqueda: RSS